On October 5, 2026, the clinical trial registry listed an update for a study involving teduglutide, marketed as GATTEX. The study, titled "A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)," is registered under identifier NCT05561647. Its status is recorded as completed. No phase classification was listed for this study. The trial was designed as a survey assessing knowledge among participants and physicians using GATTEX, according to the registry title. No additional details such as results, findings, or outcome data were included in this update. This brief reflects only the status change recorded in the registry entry and does not characterize the survey's conclusions or any data collected. Teduglutide remains an approved compound. Readers interested in background on teduglutide, including its approved uses and regulatory history, can consult the compound overview for further context.
Teduglutide (GATTEX) Knowledge Survey Trial Marked Completed
See the full teduglutide overview
Source: https://clinicaltrials.gov/study/NCT05561647